What if the first brain-computer implant wins broad FDA approval?
First broad FDA approval of a paralysis BCI ignites a neurotech-stock surge (Neuralink-adjacent, Synchron, Blackrock peers) and a medtech arms race — concentrated medtech upside, not a broad GPU/Tesla productivity bid. Rhymes with the 2023 surgical-robot and 2024 GLP-1 device re-ratings that lifted the theme, not the index. The robot_productivity-driven semis cascade overstates breadth; impact is narrow medtech.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. First brain-computer-interface implant wins broad FDA approval for paralysis, igniting neurotech-stock surge and medtech arms race. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.